ReviewJournal of gastrointestinal cancer2026
Redefining First-Line HER2-Positive Advanced Gastric Cancer: From Trastuzumab-Based Chemoimmunotherapy to Zanidatamab and Next-Generation HER2 Targeting.
Tamotsu Sagawa et al.PubMed ↗Publisher ↗
No numbers read from the abstract.